HSP90AB1 and lymphoma: In light of the reported, several HSP90 inhibitors such as alvespimycin (NCT01126502), luminespib (NCT01485536), PU-H71 (NCT01581541) and SNX-5422 (NCT02914327) currently are assessed in clinical trials for the treatment of lymphoma patients.